Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera

Claire Harrison • 12 Jun 2015
EHA 2015
Myeloproliferative Neoplasms Ruxolitinib

At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, provides an update on the phase 3 RESPONSE trial, which compared the JAK1/2 inhibitor, ruxolitinib, versus best available therapy in patients with polycythemia vera who were intolerant of or resistant to first-line therapy with hydroxyurea.

More from Claire Harrison

16:35
Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
Claire Harrison et al. • 11 Dec 2023
1:58
The value of novel JAK2 and CALR-targeted therapies in MPNs
Claire Harrison • 24 Apr 2023
1:39
The role of transplantation in MPNs & factors to consider when selecting patients for transplant
Claire Harrison • 24 Apr 2023
2:33
Optimizing current treatment approaches in myelofibrosis
Claire Harrison • 24 Apr 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals